Artelo Biosciences (ARTL) Competitors $0.95 0.00 (-0.39%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. SYBX, ERNA, MRKR, CLDI, RLYB, HOTH, NXTC, IMNN, NERV, and BCTXShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include Synlogic (SYBX), Eterna Therapeutics (ERNA), Marker Therapeutics (MRKR), Calidi Biotherapeutics (CLDI), Rallybio (RLYB), Hoth Therapeutics (HOTH), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Synlogic Eterna Therapeutics Marker Therapeutics Calidi Biotherapeutics Rallybio Hoth Therapeutics NextCure Imunon Minerva Neurosciences BriaCell Therapeutics Artelo Biosciences (NASDAQ:ARTL) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings. Does the media refer more to ARTL or SYBX? In the previous week, Artelo Biosciences' average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score. Company Overall Sentiment Artelo Biosciences Neutral Synlogic Neutral Which has more volatility and risk, ARTL or SYBX? Artelo Biosciences has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Do insiders & institutionals believe in ARTL or SYBX? 0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.8% of Artelo Biosciences shares are owned by insiders. Comparatively, 3.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ARTL or SYBX more profitable? Artelo Biosciences' return on equity of -104.59% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -104.59% -94.06% Synlogic N/A -207.84%-114.81% Which has higher earnings and valuation, ARTL or SYBX? Artelo Biosciences has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.29M-$2.99-0.32Synlogic$8K1,659.37-$57.28M-$2.51-0.45 Do analysts recommend ARTL or SYBX? Artelo Biosciences presently has a consensus target price of $5.50, indicating a potential upside of 479.56%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Artelo Biosciences is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer ARTL or SYBX? Synlogic received 281 more outperform votes than Artelo Biosciences when rated by MarketBeat users. However, 78.13% of users gave Artelo Biosciences an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformArtelo BiosciencesOutperform Votes5078.13% Underperform Votes1421.88% SynlogicOutperform Votes33169.54% Underperform Votes14530.46% SummaryArtelo Biosciences beats Synlogic on 9 of the 15 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.11M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.339.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.236.406.744.50Net Income-$9.29M$143.98M$3.23B$248.32M7 Day Performance0.96%1.90%1.49%-0.03%1 Month Performance-18.19%4.01%11.47%12.72%1 Year Performance-37.77%-3.00%16.57%7.38% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.33 of 5 stars$0.95-0.4%$5.50+479.6%-36.9%$3.11MN/A-0.335SYBXSynlogicN/A$1.13+0.9%N/A-30.9%$13.10M$8,000.00-0.2780High Trading VolumeERNAEterna Therapeutics0.7596 of 5 stars$0.21+5.2%N/A-88.9%$13.10M$582,000.00-0.0310MRKRMarker Therapeutics4.1155 of 5 stars$1.14-1.7%$13.17+1,055.0%-72.5%$12.90M$6.59M-0.9560Analyst RevisionGap UpCLDICalidi Biotherapeutics1.9305 of 5 stars$0.44-3.3%$15.00+3,279.9%N/A$12.63M$50,000.000.0038RLYBRallybio1.8773 of 5 stars$0.30+2.7%$10.00+3,223.4%-79.8%$12.52M$636,000.00-0.1940Gap DownHOTHHoth Therapeutics3.2945 of 5 stars$0.93-2.5%$4.00+330.5%-29.5%$12.24MN/A-0.704NXTCNextCure3.9591 of 5 stars$0.43-2.6%$3.50+705.9%-69.7%$12.18MN/A-0.2190IMNNImunon1.5756 of 5 stars$0.82+2.0%$21.50+2,535.1%-72.3%$11.93M$500,000.00-0.4330News CoverageAnalyst ForecastGap UpNERVMinerva Neurosciences2.9324 of 5 stars$1.66+2.9%$5.00+201.9%-41.1%$11.58MN/A-3.769News CoverageAnalyst ForecastBCTXBriaCell Therapeutics1.3105 of 5 stars$3.12+0.3%$32.00+925.6%-84.5%$11.57MN/A-0.238 Related Companies and Tools Related Companies Synlogic Alternatives Eterna Therapeutics Alternatives Marker Therapeutics Alternatives Calidi Biotherapeutics Alternatives Rallybio Alternatives Hoth Therapeutics Alternatives NextCure Alternatives Imunon Alternatives Minerva Neurosciences Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
